Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival

Glioblastoma-multiforme (GBM), the most aggressive glial tumor, has a worldwide age-adjusted incidence ranging from 0.59-3.69/100000 persons. Despite current multimodal-treatment approach, median-survival time and progression-free survival (PFS) remains short. Glioblastomas display a variety of mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Puneet, Khare, Richa, Garg, Nitin, Sorte, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480073/
https://www.ncbi.nlm.nih.gov/pubmed/28685138
http://dx.doi.org/10.12998/wjcc.v5.i6.247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480073/
https://www.ncbi.nlm.nih.gov/pubmed/28685138
http://dx.doi.org/10.12998/wjcc.v5.i6.247

Ejemplares similares